Matinas BioPharma Holdings Inc (NASDAQ:MTNB) is scheduled to be issuing its quarterly earnings data on Monday, November 13th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

Matinas BioPharma Holdings (NASDAQ:MTNB) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.02 million. Matinas BioPharma Holdings had a negative net margin of 8,834.65% and a negative return on equity of 143.22%.

Matinas BioPharma Holdings Inc (NASDAQ:MTNB) opened at $1.10 on Monday. Matinas BioPharma Holdings Inc has a 1-year low of $1.01 and a 1-year high of $3.99.

In related news, Director Adam K. Stern purchased 100,000 shares of Matinas BioPharma Holdings stock in a transaction dated Friday, September 8th. The stock was bought at an average price of $1.38 per share, for a total transaction of $138,000.00. Following the completion of the acquisition, the director now directly owns 793,992 shares of the company’s stock, valued at $1,095,708.96. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought 110,000 shares of company stock valued at $151,250 in the last quarter.

A hedge fund recently bought a new stake in Matinas BioPharma Holdings stock. California State Teachers Retirement System purchased a new position in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 93,500 shares of the company’s stock, valued at approximately $158,000. California State Teachers Retirement System owned approximately 0.10% of Matinas BioPharma Holdings at the end of the most recent quarter.

MTNB has been the subject of several research analyst reports. Maxim Group set a $6.00 price target on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Tuesday, August 8th. Roth Capital set a $9.00 price target on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Thursday, August 10th.

ILLEGAL ACTIVITY WARNING: “Matinas BioPharma Holdings Inc (MTNB) Set to Announce Quarterly Earnings on Monday” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/matinas-biopharma-holdings-inc-mtnb-set-to-announce-quarterly-earnings-on-monday/1682151.html.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Earnings History for Matinas BioPharma Holdings (NASDAQ:MTNB)

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.